The government gives orphan drug producers special incentives, such as enhanced patent protection and marketing rights. Because BioMarin's enzyme replacement therapies are the only products on the market for the rare genetic diseases that they treat, Cramer said, the company can charge "a great deal of money." The company has three drugs on the U.S. market and a fourth in Europe, but Cramer said the reason to own the stock is for its pipeline, which includes three major catalysts coming in the second half of the year. Cramer welcomed BioMarin CEO Jean-Jacques Bienaime to "Mad Money," calling the company one of the "single most exciting biotech companies I've ever had on the show." Bienaime described BioMarin's business model as the "opposite of bit pharma," in a sense, because it seeks a "very significant efficacy or safety improvement in a very small patient population." He agreed with Cramer that because BioMarin's therapies are so effective, otherwise "stingy" health companies are willing to pay up for them. At the same time, said Bienaime, BioMarin's leading drug treats only 1,200 patients worldwide, "so it's never going to have a significant impact" on health companies' budgets. Because BioMarin's patient populations are so desperate for treatment, its development times are much shorter than the industry average. "Because patient population is so limited, regulatory authorities cannot ask us for a very large clinical trial size," Bienaime explained. Cramer told Bienaime that he's been "in awe" of BioMarin for a long time, calling it the son of Genzyme ( GENZ), which Cramer said was "one of the biggest hits I have ever seen." BioMarin doesn't "need a takeover to make a lot of money," he said, "but I can't believe that one of these major pharmaceutical companies is going to let this company stay independent forever."